Dendreon reports Provenge sales

Dendreon Corp. (NASDAQ:DNDN) said late Wednesday that revenues for prostate cancer treatment Provenge sipuleucel-T were $20.2 million in 3Q10 and about $9.5 million in October. The Street was expecting 3Q revenue of $23.8 million. The company said the autologous cell therapy has received over 1,000 prescriptions since its approval in April.

Dendreon noted on its quarterly conference call that it has not observed any "major impact" on Provenge prescriptions as a result of the National Coverage Analysis initiated by CMS in June. On Nov. 17, CMS's Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) will meet to discuss the use of Provenge. ...